Pierpaolo Di Micco

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6455567/publications.pdf

Version: 2024-02-01

41 papers

595 citations

759233 12 h-index 677142 22 g-index

42 all docs 42 docs citations

times ranked

42

1084 citing authors

#	Article	IF	Citations
1	Clinical impact of pre-admission antithrombotic therapy in hospitalized patients with COVID-19: A multicenter observational study. Pharmacological Research, 2020, 159, 104965.	7.1	97
2	Clotting Factors in COVID-19: Epidemiological Association and Prognostic Values in Different Clinical Presentations in an Italian Cohort. Journal of Clinical Medicine, 2020, 9, 1371.	2.4	63
3	Clinical characteristics and prognosis of hospitalized COVIDâ€19 patients with incident sustained tachyarrhythmias: A multicenter observational study. European Journal of Clinical Investigation, 2020, 50, e13387.	3.4	54
4	Prothrombotic gene variants as risk factors of acute myocardial infarction in young women. Journal of Translational Medicine, 2012, 10, 235.	4.4	35
5	Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination. International Journal of Environmental Research and Public Health, 2021, 18, 904.	2.6	32
6	Prognostic Value of Fibrinogen among COVID-19 Patients Admitted to an Emergency Department: An Italian Cohort Study. Journal of Clinical Medicine, 2020, 9, 4134.	2.4	28
7	Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. Journal of Cardiovascular Pharmacology, 2020, 76, 369-371.	1.9	24
8	Thromboprofilaxys With Fondaparinux vs. Enoxaparin in Hospitalized COVID-19 Patients: A Multicenter Italian Observational Study. Frontiers in Medicine, 2020, 7, 569567.	2.6	21
9	Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study. Journal of Blood Medicine, 2021, Volume 12, 69-75.	1.7	16
10	Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients. Frontiers in Pharmacology, 2020, 11, 582348.	3.5	15
11	Cardiovascular Comorbidities and Pharmacological Treatments of COVID-19 Patients Not Requiring Hospitalization. International Journal of Environmental Research and Public Health, 2021, 18, 102.	2.6	15
12	Clinical Outcome of Edoxaban vs. Vitamin K Antagonists in Patients with Atrial Fibrillation and Diabetes Mellitus: Results from a Multicenter, Propensity-Matched, Real-World Cohort Study. Journal of Clinical Medicine, 2020, 9, 1621.	2.4	13
13	Home Management of Patients with Moderate or Severe Respiratory Failure Secondary to COVID-19, Using Remote Monitoring and Oxygen with or without HFNC. Pathogens, 2021, 10, 413.	2.8	13
14	Administration of Immunoglobulins in SARS-CoV-2-Positive Patient Is Associated With Fast Clinical and Radiological Healing: Case Report. Frontiers in Medicine, 2020, 7, 388.	2.6	12
15	Venous Thromboembolism and Its Association with COVID-19: Still an Open Debate. Medicina (Lithuania), 2020, 56, 506.	2.0	12
16	New-Onset Atrial Fibrillation and Early Mortality Rate in COVID-19 Patients: Association with IL-6 Serum Levels and Respiratory Distress. Medicina (Lithuania), 2022, 58, 530.	2.0	12
17	Preadmission Statin Therapy and Clinical Outcome in Hospitalized Patients With COVID-19: An Italian Multicenter Observational Study. Journal of Cardiovascular Pharmacology, 2021, 78, e94-e100.	1.9	11
18	Heparin and SARS-CoV-2: Multiple Pathophysiological Links. Viruses, 2021, 13, 2486.	3.3	10

#	Article	IF	CITATIONS
19	Alpha-1 Antitrypsin Screening in a Selected Cohort of Patients Affected by Chronic Pulmonary Diseases in Naples, Italy. Journal of Clinical Medicine, 2021, 10, 1546.	2.4	9
20	Pre-admission atrial fibrillation in COVID-19 patients: Prevalence and clinical impact. European Journal of Internal Medicine, 2021, 88, 133-135.	2.2	9
21	The Impact of Risk-Adjusted Heparin Regimens on the Outcome of Patients with COVID-19 Infection. A Prospective Cohort Study. Viruses, 2021, 13, 1720.	3.3	9
22	The Angiotensin Converting Enzyme Deletion/Deletion Genotype Is a Risk Factor for Severe COVID-19: Implication and Utility for Patients Admitted to Emergency Department. Medicina (Lithuania), 2021, 57, 844.	2.0	9
23	Pathophysiology of Vaccine-Induced Prothrombotic Immune Thrombocytopenia (VIPIT) and Vaccine-Induced Thrombocytopenic Thrombosis (VITT) and Their Diagnostic Approach in Emergency. Medicina (Lithuania), 2021, 57, 997.	2.0	9
24	Rlood Targets of Adjuvant Drugs Against COVID19. Journal of Blood Medicine, 2020, Volume 11, 237-241.	1.7	7
25	Molecular Analysis of Prothrombotic Gene Variants in Patients with Acute Ischemic Stroke and with Transient Ischemic Attack. Medicina (Lithuania), 2021, 57, 723.	2.0	7
26	Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience. Healthcare (Switzerland), 2021, 9, 1108.	2.0	7
27	Clinical Differences between COVID-19 and a COVID-Like Syndrome. Journal of Clinical Medicine, 2021, 10, 2519.	2.4	6
28	Acute Pancreatitis and COVID-19: A Single-Center Experience. Journal of Multidisciplinary Healthcare, 2021, Volume 14, 2857-2861.	2.7	6
29	Machine Learning to Calculate Heparin Dose in COVID-19 Patients with Active Cancer. Journal of Clinical Medicine, 2022, 11, 219.	2.4	6
30	Fondaparinux and bleeding risk in COVID-19: unsolved question. Thrombosis Research, 2021, 200, 128-129.	1.7	5
31	Sex-Specific Impact of Different Obesity/Metabolic Phenotypes on Long-Term Cardiovascular Outcomes in Acute Coronary Syndrome Patients. Biomedicines, 2022, 10, 424.	3.2	5
32	Resolution of Disseminated Intravascular Coagulation in a Patient with COVID-19 and Associated Sepsis—Induced Neutropenia. Medicina (Lithuania), 2021, 57, 106.	2.0	4
33	<p>Physical Activity and Thrombophilic Risk in a Short Series</p> . Journal of Blood Medicine, 2020, Volume 11, 39-42.	1.7	3
34	Prevalence of Pulmonary Hypertension in an Unselected Community-Based Population: A Retrospective Echocardiographic Studyâ€"RES-PH Study. Journal of Personalized Medicine, 2021, 11, 489.	2.5	2
35	Compromised Lung Volume and Hemostatic Abnormalities in COVID-19 Pneumonia: Results from an Observational Study on 510 Consecutive Patients. Journal of Clinical Medicine, 2021, 10, 2894.	2.4	2
36	Antithrombotic drugs with adjuvant action against COVID-19. Italian Journal of Medicine, 2020, 14, 241-244.	0.3	1

PIERPAOLO DI MICCO

#	Article	IF	CITATIONS
37	Thrombotic Disorders and Antithrombotic Treatments Special Issue. Medicina (Lithuania), 2022, 58, 229.	2.0	1
38	Prognostic Impact of Active Cigarette Smoking on Mortality in Patients with Acute Venous Thromboembolic Events, Findings from Real World Data. Medicina (Lithuania), 2022, 58, 295.	2.0	1
39	Editorial: Unusual Clinical Presentation of COVID-19. Journal of Clinical Medicine, 2022, 11, 2953.	2.4	1
40	Lesson learned by COVID-19 outbreak: multilevel triage strategies in patients admitted to the emergency room in southern Italy. Italian Journal of Medicine, $2021,15,.$	0.3	0
41	Special Issue "COVID-19 and Thrombosis― Viruses, 2022, 14, 1425.	3.3	O